Infectious diseases remain one of the largest causes of preventable death around the world, with Africa as the focus of many of the most pernicious of them. 
Sub-Saharan Africa has one of the highest rates of HIV infections in the world, and also has a large presence of both TB and Malaria. As these diseases are further researched, it is vital for doctors and medical professionals to be on the cutting edge of medicines and practice.
The looming threat of antibiotic resistant strains of deadly diseases such as TB and Malaria is a pivotal issue which will be discussed at the upcoming Africa Health Congress and Exhibition taking place at the Gallagher Convention Centre in Midrand from 7 to 9 May 2013.
While many parts of Africa are coming to terms with the possibility of TB, which is immune to the effects of the current generation of antibiotics, many in Europe are dealing with the continuing growth of hospital borne pathogens which resist many conventional treatments.
Additionally, there is growing research into human immunity and vital work is being done with those who have natural immunity or resistance to emerging illnesses.
The Africa Health panel of experts will offer delegates a two-day CPD accredited review designed to provide up-to-date information on diagnosing, treating and preventing a wide range of infectious diseases throughout the African continent at the third Pan-African Infectious Diseases Conference.
“One of the most promising fields of scientific research is the focus on people who show immunity and resistance to emerging illnesses. The challenge we’re facing is that some infectious diseases like TB are becoming more difficult to treat.
“During the 1930s, dedicated sanitaria and invasive surgery were commonly prescribed for those with the infection – usually caused by Mycobacterium tuberculosis – which is the most successful human pathogen of all time,” says Gavin Churchyard, founder and CEO of Aurum Institute for Health Research.
Early TB detection of the disease will help in addressing the TB problem and initiate the appropriate TB treatment. In recent years, new approaches to diagnosing both drug sensitive and resistant TB have been evaluated.
To effectively address the MDR problem countries need to scale up diagnostic services and similarly scale up treatment services. This should be implemented in combination with other strategies such as initiating anti-retroviral therapy in HIV infected individuals and isoniazid preventive therapy among HIV infected individual who do not have TB.